Patent · US Active

Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

US12128033B2 · kind B2 · utility

1Cited by

23References

18Claims

0Family size

Assignees

Neurocrine Biosciences, Inc. · US
Sanofi · FR

Inventors

Andrew J. Becker · Bellevue, US
Joel Radisson · Paris, FR

Key dates

Filing date	Mar 14, 2024
Grant date	Oct 29, 2024
Priority date	—
Expiry date	Mar 14, 2044

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thi-azol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.